These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34996522)

  • 1. Plasma MCP-1 and changes on cognitive function in community-dwelling older adults.
    Sanchez-Sanchez JL; Giudici KV; Guyonnet S; Delrieu J; Li Y; Bateman RJ; Parini A; Vellas B; de Souto Barreto P;
    Alzheimers Res Ther; 2022 Jan; 14(1):5. PubMed ID: 34996522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of Plasma Amyloid-β42/40 and Cognitive Decline Among Community-Dwelling Older Adults.
    Giudici KV; de Souto Barreto P; Guyonnet S; Li Y; Bateman RJ; Vellas B;
    JAMA Netw Open; 2020 Dec; 3(12):e2028634. PubMed ID: 33331917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions Between Weight Loss and Plasma Neurodegenerative Markers for Determining Cognitive Decline Among Community-Dwelling Older Adults.
    Giudici KV; Guyonnet S; Morley JE; Nguyen AD; Aggarwal G; Parini A; Li Y; Bateman RJ; Vellas B; de Souto Barreto P;
    J Gerontol A Biol Sci Med Sci; 2022 Jun; 77(6):1159-1168. PubMed ID: 35034116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Periostin Plasma Levels and Changes on Physical and Cognitive Capacities in Community-Dwelling Older Adults.
    Sánchez-Sánchez JL; Ader I; Jeanson Y; Planat-Benard V; Vellas B; Casteilla L; de Souto-Barreto P
    J Gerontol A Biol Sci Med Sci; 2023 Mar; 78(3):424-432. PubMed ID: 36373873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Aβ and neurofilament light chain are associated with cognitive and physical function decline in non-dementia older adults.
    He L; de Souto Barreto P; Aggarwal G; Nguyen AD; Morley JE; Li Y; Bateman RJ; Vellas B;
    Alzheimers Res Ther; 2020 Oct; 12(1):128. PubMed ID: 33032662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    Donohue MC; Sperling RA; Petersen R; Sun CK; Weiner MW; Aisen PS;
    JAMA; 2017 Jun; 317(22):2305-2316. PubMed ID: 28609533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations Between Blood-Based Biomarkers and Cognitive and Functional Trajectories Among Participants of the MEMENTO Cohort.
    Grasset L; Bouteloup V; Cacciamani F; Pellegrin I; Planche V; Chêne G; Dufouil C;
    Neurology; 2024 May; 102(9):e209307. PubMed ID: 38626384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma p-tau181 as an outcome and predictor of multidomain intervention effects: a secondary analysis of a randomised, controlled, dementia prevention trial.
    Coley N; Zetterberg H; Cantet C; Guyonnet S; Ashton NJ; Vellas B; Blennow K; Andrieu S;
    Lancet Healthy Longev; 2024 Feb; 5(2):e120-e130. PubMed ID: 38310892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.
    He L; Morley JE; Aggarwal G; Nguyen AD; Vellas B; de Souto Barreto P;
    Sci Rep; 2021 Jun; 11(1):13394. PubMed ID: 34183688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Episodic Memory Tests for Screening in Clinical Trials for Early Alzheimer's Disease: A Comparison of the Free and Cued Selective Reminding Test (FCSRT) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
    Teng E; Manser PT; Shah M; Pickthorn K; Hu N; Djakovic S; Swendsen H; Blendstrup M; Faccin G; Ostrowitzki S; Sink KM
    J Prev Alzheimers Dis; 2023; 10(1):41-49. PubMed ID: 36641609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.
    Schindler SE; Jasielec MS; Weng H; Hassenstab JJ; Grober E; McCue LM; Morris JC; Holtzman DM; Xiong C; Fagan AM
    Neurobiol Aging; 2017 Aug; 56():25-32. PubMed ID: 28482211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the combination of plasma amyloid-beta and geroscience biomarkers on the incidence of clinically meaningful cognitive decline in older adults.
    Lu WH; Giudici KV; Morley JE; Guyonnet S; Parini A; Aggarwal G; Nguyen AD; Li Y; Bateman RJ; Vellas B; de Souto Barreto P;
    Geroscience; 2022 Jun; 44(3):1489-1503. PubMed ID: 35445358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kidney Function and Cognitive Decline in Older Adults: Examining the Role of Neurodegeneration.
    Guerville F; De Souto Barreto P; Coley N; Andrieu S; Mangin JF; Chupin M; Payoux P; Ousset PJ; Rolland Y; Vellas B;
    J Am Geriatr Soc; 2021 Mar; 69(3):651-659. PubMed ID: 33217785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Associations between Plasma Amyloid-Beta 42/40 and Frailty in Community-Dwelling Older Adults.
    Lu WH; Giudici KV; Rolland Y; Guyonnet S; Li Y; Bateman RJ; de Souto Barreto P; Vellas B
    J Prev Alzheimers Dis; 2021; 8(1):41-47. PubMed ID: 33336223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.
    Oliveira Monteiro MPA; Salheb Oliveira DSM; Manzine PR; Crispim Nascimento CM; Dos Santos Orlandi AA; de Oliveira Gomes GA; Dos Santos Orlandi F; Zazzetta MS; Pott-Junior H; Cominetti MR
    Alzheimers Res Ther; 2021 Jan; 13(1):18. PubMed ID: 33419480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma inflammation-related biomarkers are associated with intrinsic capacity in community-dwelling older adults.
    Lu WH; Gonzalez-Bautista E; Guyonnet S; Lucas A; Parini A; Walston JD; Vellas B; de Souto Barreto P;
    J Cachexia Sarcopenia Muscle; 2023 Apr; 14(2):930-939. PubMed ID: 36660894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive decline as an outcome and marker of progression toward dementia, in early preventive trials.
    Mura T; Coley N; Amieva H; Berr C; Gabelle A; Ousset PJ; Vellas B; Andrieu S;
    Alzheimers Dement; 2022 Apr; 18(4):676-687. PubMed ID: 34482607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.